Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study

Febrile neutropenia (FN) occurrence outside of clinical trials: occurrence and predictive factors in adult patients treated with chemotherapy and an expected moderate FN risk. Rationale and design of a real-world prospective, observational, multinational study

Abstract Background Febrile neutropenia (FN) is a common occurrence during chemotherapy. Granulocyte colony-stimulating factors (G-CSFs) can significantly reduce the risk of FN. International guidelines recommend G-CSF for patients receiving chemotherapy with FN risk of ≥20% or 10% to 20% with defin...

Full description

Bibliographic Details
Main Authors: Bernardo Leon Rapoport, Matti Aapro, Marianne Paesmans, Ronwyn van Eeden, Teresa Smit, Andriy Krendyukov, Jean Klastersky
Format: Article
Language:English
Published: BMC 2018-09-01
Series:BMC Cancer
Subjects:
Chemotherapy-induced neutropenia
Febrile neutropenia
Neutropenia
Chemotherapy
Cytotoxic chemotherapy
Myelosuppressive chemotherapy
Online Access:http://link.springer.com/article/10.1186/s12885-018-4838-z

Internet

http://link.springer.com/article/10.1186/s12885-018-4838-z

Similar Items